Research programme: small molecule drugs - Astex/Bayer HealthCare Pharmaceuticals

Drug Profile

Research programme: small molecule drugs - Astex/Bayer HealthCare Pharmaceuticals

Latest Information Update: 25 Jul 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astex Therapeutics; Bayer Schering Pharma
  • Developer Astex Therapeutics; Bayer HealthCare Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 20 Jul 2011 Astex Therapeutics has been acquired by SuperGen
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 26 Mar 2010 Preclinical development is ongoing in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top